id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2503045,722bc939-29af-4b51-b7e6-55a1c5815200,3T,"THE PETRIZZO GROUP, INC.",305932,OMEROS CORPORATION,2020,third_quarter,MED,Advocated for Medicare Part B packaged payment reforms; and the expansion of the non-opioid pain management drug exclusion to the drugs functioning as supplies during a surgical procedure packaging policy. NO PAIN Act,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,1,2020-09-24T13:27:20.283000-04:00
2503280,2b34b2d0-3b43-412f-8e2a-ec7da6fb999d,Q3,"CONGRESSIONAL SOLUTIONS, INC (CSI)",297237,UNIVERSITY OF NORTH TEXAS SYSTEM,2020,third_quarter,MED,"COVID19 Research 
COVID 19 Testing","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-09-30T22:55:43.490000-04:00
2503296,d9fab1de-a3c5-4f1c-91f4-f1f652cb837f,Q3,"FRANCIS EDWARD & CRONIN, INC.",311314,CURE ALZHEIMER'S FUND,2020,third_quarter,MED,Issues and legislation related to Alzheimer's disease research,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",20000,,0,0,2020-10-01T07:49:50.503000-04:00
2503297,29c172f7-0b0e-4508-a957-203330979f63,Q3,"FRANCIS EDWARD & CRONIN, INC.",311314,"PATH DECISION SUPPORT SOFTWARE, LLC",2020,third_quarter,MED,Issues and legislation related to diabetes treatment and diagnosis,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,,0,0,2020-10-01T07:53:50.997000-04:00
2503415,d8f0a72a-1a1e-4ef0-83fb-95620d1a94ae,Q3,"RICHARD J. SCHOLZ, P.A. (FKA JACOBS SCHOLZ & WYLER, LLC)",400361684,PPLA,2020,third_quarter,MED,Pharmaceutical labeling,Food & Drug Administration (FDA),18700,,0,0,2020-10-02T10:36:44.857000-04:00
2503722,ba5c4e91-e331-4b26-a5f8-758e15d96b4e,Q3,NATURAL RESOURCE RESULTS LLC,321555,SHINE MEDICAL TECHNOLOGIES,2020,third_quarter,MED,Support NNSA budget and approps for grants to cooperatives on medical isotope MO-99 production facility.,"HOUSE OF REPRESENTATIVES,SENATE,White House Office",30000,,0,0,2020-10-04T10:55:08.773000-04:00
2503752,3fd219c5-93f5-43fd-a177-01d4885d215f,Q3,MARSHALL BRACHMAN,6848,BAYLOR SCOTT AND WHITE HEALTH -- FORMERLY BAYLOR HEALTH CARE SYSTEM,2020,third_quarter,MED,support funding for medical research programs,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-04T15:51:27.970000-04:00
2503961,86458043-1203-4eef-8001-d0876b4de9f1,Q3,WATKINS & EAGER PLLC,401104403,NATIONAL FRAGILE X FOUNDATION,2020,third_quarter,MED,Work to assist in developing a legislative strategy for funding for training & development for Fragile X clinicians & other medical providers.  Encourage Members to act favorably on matters of interest related to funding & research.,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2020-10-05T13:05:53.047000-04:00
2504000,9d4e540a-0a2e-4b17-b3b9-5a8d7f76dc4e,Q3,HOLLAND & KNIGHT LLP,18466,NETEERA TECHNOLOGIES LTD.,2020,third_quarter,MED,Contactless and remote vital sign monitoring technology.,"Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-05T13:49:08.333000-04:00
2504098,90e37133-7139-4887-a5a5-debd936fafed,Q3,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2020,third_quarter,MED,"NIH Budget, PCORI re authorization, NICHD budget, sickle cell research, CHGME, 340B, surprise billing legislation, screening and enrollment issues, pediatric research bill HR4519 PACT Act, COVID related testing and research.  Executive ICE rule on changing status for J1 visas","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",,35404,0,0,2020-10-05T16:33:48.187000-04:00
2504297,dc8ff6f0-ad34-4094-905b-c91d72ae2822,Q3,TODD STRATEGY GROUP,401103321,ORGANIZE.ORG,2020,third_quarter,MED,Organ procurement policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-06T12:27:37.290000-04:00
2504396,5a11903c-a343-49af-9108-18f797c1fc85,Q3,BEN BARNES GROUP LP,5415,ENVIGO RMS LLC,2020,third_quarter,MED,Medical/Disease Research,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-10-06T15:12:28.400000-04:00
2504403,8d4b5a19-18d3-4466-9373-edac4b329e64,Q3,"AUBURN HEALTH STRATEGIES, LLC",292697,"NEUROTECH, LLC",2020,third_quarter,MED,EEG monitoring,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-06T15:29:31.693000-04:00
2504406,fde6a4ba-e6fd-4386-9e84-eb29989c9b6f,Q3,"AUBURN HEALTH STRATEGIES, LLC",292697,AMERICAN PROFICIENCY INSTITUTE,2020,third_quarter,MED,Proficiency testing for clinical laboratories,"Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-06T15:39:33.587000-04:00
2504655,0e14125c-af0d-4f2a-855e-d1980d99bb1b,Q3,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2020,third_quarter,MED,Focus interactions with the Agency for Healthcare Research and Quality (AHRQ) on the issue of Quality of Medication Therapy Management Services delivered programs authorized by the Patient Protection and Affordable Care Act (PPACA PL 111-148) and Medicare Part D plans.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2020-10-07T13:29:08.140000-04:00
2505319,6b232a02-74a7-4358-a462-6a02c74e2960,Q3,RAY C CULVER III,11468,ARKANSAS CHILDREN'S HOSPITAL,2020,third_quarter,MED,Funding for USDA ARS Human Nutrition Research Centers in the FY2021 House and Senate Agricultural Appropriations bills and finalizing the cooperative agreement for FY20 funding.,"HOUSE OF REPRESENTATIVES,SENATE",5000,,0,0,2020-10-08T18:24:49.527000-04:00
2505460,22a2bad9-fd3c-4c00-a8c3-20686419f988,Q3,"THE CJR GROUP, INC.",288293,UNIVERSITY HOSPITALS HEALTH SYSTEM,2020,third_quarter,MED,"NIH funding, mental health initiatives","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-09T10:26:36.087000-04:00
2505519,b1545e10-607d-4377-9fee-920c351acd24,Q3,GOLDBUG STRATEGIES LLC,400701094,COALITION FOR 21ST CENTURY MEDICINE,2020,third_quarter,MED,"in vitro diagnostics, clinical laboratories, digital health regulation","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-10-09T11:18:27.200000-04:00
2505592,ea3f8c93-ba4b-48d6-ba3a-eb1b2c378e40,Q3,SAINT LOUIS UNIVERSITY,400684039,SAINT LOUIS UNIVERSITY,2020,third_quarter,MED,Support for infectious disease research and research related to COVID-19.,"HOUSE OF REPRESENTATIVES,SENATE",,10000,0,0,2020-10-09T12:15:16.567000-04:00
2505678,f5226059-fb54-4c6c-8462-a8e6bc7747a8,Q3,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,401103437,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,2020,third_quarter,MED,"COVID-19 Testing
PPE Access","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-09T12:49:02.517000-04:00
2505717,8d9f29a6-cb50-4368-99cc-a374990a4098,Q3,"FEDERAL SOLUTIONS, LLC",311371,MISSISSIPPI STATE UNIVERSITY,2020,third_quarter,MED,Labor/HHS/Education Appropriations: Provisions relating to disease research.,"Education, Dept of,HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Oceanic & Atmospheric Administration (NOAA),SENATE",50000,,0,0,2020-10-09T13:56:33.583000-04:00
2505772,c90eb463-cb5e-40a9-93a5-a9d4caad34e1,Q3,SQUIRE PATTON BOGGS,30906,ALLIANCE FOR BIOSECURITY,2020,third_quarter,MED,Preparedness and response as it relates to Biosecurity.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",100000,,0,0,2020-10-09T14:49:51.270000-04:00
2505912,560d7338-9f63-4708-b7da-52021c2a4a93,Q3,"MOLNLYCKE HEALTH CARE US, LLC",401104898,"MOLNLYCKE HEALTH CARE US, LLC",2020,third_quarter,MED,Pursuance of approval from relevant agencies of a medical pilot program; gathering support from Congressional leaders.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,80000,0,0,2020-10-10T17:24:46.343000-04:00
2505955,577d01be-624e-41c3-b32c-74c826a4774b,Q3,HOLLAND & KNIGHT LLP,18466,NOVEOME BIOTHERAPEUTICS,2020,third_quarter,MED,Pending clinical issues before the FDA; COVID-19 pandemic related issues before Congress and the Development Finance Corporation.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-11T13:16:20.627000-04:00
2506600,bb6e40b7-fb6f-4c68-b585-51d9a0228cc7,Q3,GREEN PLAINS INC.,401104765,GREEN PLAINS,2020,third_quarter,MED,"Issues related to the Novel Coronavirus and the disease COVID-19; Issues related to the production of industrial grades of alcohol for inclusion in hand sanitizer; Issues related to the transportation and tax treatment for industrial grades of alcohol for inclusion in hand sanitizer; H.R. 748, the CARES Act; H.R. 6800, the Heroes Act;","Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Energy, Dept of,Environmental Protection Agency (EPA),Federal Emergency Management Agency (FEMA),Federal Reserve System,Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Treasury, Dept of,U.S. Trade Representative (USTR),White House Office",,70000,0,0,2020-10-13T11:09:49.857000-04:00
2506633,ab398a89-dd5b-4661-bcd7-b25de568b9ef,Q3,SQUIRE PATTON BOGGS,30906,"IMPACT JOURNALS, LLC",2020,third_quarter,MED,National Library of Medicine indexing matters.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-13T11:36:17.430000-04:00
2506642,6a44cc4c-b512-4ece-a2b9-b661581b39d8,Q3,BLUEBIRD STRATEGIES,401105447,MYOTONIC,2020,third_quarter,MED,Increasing funding for Myotonic Dystrophy research. Fiscal year 2020 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-13T11:41:29.880000-04:00
2506660,e37efc0e-71d3-4aa9-aa87-1a6d62996db1,Q3,SQUIRE PATTON BOGGS,30906,"LA MAESTRA FOUNDATION ON BEHALF OF LA MAESTRA FAMILY CLINIC, INC.",2020,third_quarter,MED,Funding support for federally qualified health centers; reauthorization of programs,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-13T11:47:42.763000-04:00
2506666,704757c5-bdb9-4476-a83c-7f70e59a2bd2,Q3,BLUEBIRD STRATEGIES,401105447,"MYRIAD GENETICS, INC.",2020,third_quarter,MED,Legislation to regulate clinical labs under CLIA and FDA.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-13T11:47:45.300000-04:00
2506716,c303da94-b636-4db8-89b5-eecd0ba65dae,Q3,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,"MOSES WEITZMAN HEALTH SYSTEM, INC.",2020,third_quarter,MED,"Moving Forward Act, H.R. 2
Coronavirus Aid, Relief and Economic Security (CARES) Act, H.R. 748, now P.L. 116-136
Families First Coronavirus Response Act, H.R. 6201, now P.L. 116-127
Coronavirus Preparedness and Response Supplemental Appropriations Act, H.R. 6074, now P.L. 116-123
Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R. 6800
Updated Health and Economic Recovery Omnibus Emergency Solutions Act, ""The HEROES Act,"" H.R. 8406
Coronavirus Response Additional Supplemental Appropriations Act, 2020, S. 4320 
Continuing Appropriations Act, 2021, and Other Extensions Act, H.R. 8337, now. P.L. 116-159
House, Senate Department of Labor, Health & Human Services, and Education and Related Agencies Appropriations Bill
House, Senate Financial Services and General Government Appropriations Bill
House, Senate Community Health Center Reauthorization Bills
Pursuit of grants with federal agencies
House, Senate Legislation to to Reauthorize and Fund Postgraduate Nurse Practitioner Residency and Fellowship Training Programs and Medical Assistant Training Programs
House, Senate Comprehensive Addiction and Recovery Legislation
House, Senate Legislation to Reform Behavioral Health and Substance Use Disorder Prevention and Treatment
House, Senate Legislation to Fund FCC Broadband and Other Telehealth 
House, Senate Legislation to Train More Primary Care and Other Providers
House Legislation to Implement Electronic Health Provider Consultations (E-Consults) with Related 
Telemedicine in Health Centers and Rural Health Clinics, H.R. 5190 
House, Senate Infrastructure Bills (i.e., H.R. 2, H.R. 2741, H.R. 4780)","Administration for Children & Families (ACF),Agency for Healthcare Research & Quality (AHRQ),Agriculture, Dept of (USDA),Appalachian Regional Commission,Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Education, Dept of,Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Institutes of Health (NIH),Natl Telecommunications & Information Administration (NTIA),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",10000,,0,0,2020-10-13T12:20:16.647000-04:00
2506802,36212236-a9e7-4cc2-a567-1baf6d3f5f7c,Q3,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,PIH HEALTH FOUNDATION,2020,third_quarter,MED,"Moving Forward Act, H.R. 2
Coronavirus Aid, Relief and Economic Security (CARES) Act, H.R. 748, now P.L. 116-136
Families First Coronavirus Response Act, H.R. 6201, now P.L. 116-127
Coronavirus Preparedness and Response Supplemental Appropriations Act, H.R. 6074, now P.L. 116-123
Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, H.R. 6800
Updated Health and Economic Recovery Omnibus Emergency Solutions Act, ""The HEROES Act,"" H.R. 8406
Coronavirus Response Additional Supplemental Appropriations Act, 2020, S.4320
Continuing Appropriations Act, 2021, and Other Extensions Act, H.R. 8337, now. P.L. 116-159
House, Senate Department of Labor, Health & Human Services, and Education and Related Agencies Appropriations Bill
House, Senate Department of Homeland Security Appropriations Bill  
House, Senate Department of Agriculture Appropriations Bill 
Pursuit of grants with Federal agencies
Telemedicine
House, Senate Infrastructure Bills (i.e., H.R. 2, H.R. 2741, H.R. 4780)","Agency for Healthcare Research & Quality (AHRQ),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Communications Commission (FCC),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Telecommunications & Information Administration (NTIA),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",30000,,0,0,2020-10-13T13:34:33.763000-04:00
2507086,43e3c000-c234-4f8b-999e-fd12eb0a3978,Q3,"K&L GATES, LLP",32098,NATIONAL ASSN FOR BIOMEDICAL RESEARCH,2020,third_quarter,MED,Issues related to medical research (no legislation).,"Agriculture, Dept of (USDA),Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT)",20000,,0,0,2020-10-13T16:20:37.123000-04:00
2507113,0941ae35-749f-4c9b-899f-29f1b80044c3,Q3,"SAM ACTION, INC.",401104337,"SAM ACTION, INC.",2020,third_quarter,MED,"H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marihuana Research Expansion Act, to lower the barriers of researching marijuana","Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),White House Office",,20000,0,0,2020-10-13T17:10:53.370000-04:00
2507237,3995cf78-626c-4eca-bef9-ea1cdd80d511,Q3,MCDERMOTT+ LLC,401103287,COALITION FOR 21ST CENTURY MEDICINE,2020,third_quarter,MED,Issues concerning regulation of laboratory-developed tests.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",40000,,0,0,2020-10-14T08:18:31.160000-04:00
2507318,54c246c8-9344-4b67-8c4f-1c32b200b70e,Q3,SQUIRE PATTON BOGGS,30906,NATIONAL CANNABIS ROUNDTABLE,2020,third_quarter,MED,"Reforming federal law and policy governing medical research, financial transactions, and tax deductions applicable to cannabis and allowing states and territories to set and enforce their own laws governing cannabis use.","HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Treasury, Dept of,White House Office",80000,,0,0,2020-10-14T10:03:58.767000-04:00
2507361,277c1a1f-8682-42c5-997a-b1904b052215,Q3,WAKE FOREST UNIVERSITY HEALTH SCIENCES,6781,WAKE FOREST UNIVERSITY HEALTH SCIENCES,2020,third_quarter,MED,FY21 Department of Labor/HHS Appropriations bill; surprise billing,"Centers For Disease Control & Prevention (CDC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,150000,0,0,2020-10-14T10:29:12.023000-04:00
2508024,9ab799bc-bb48-4986-a3f2-502bb386a51e,Q3,FAEGRE DRINKER BIDDLE & REATH LLP,12631,GLOBAL DOWN SYNDROME FOUNDATION,2020,third_quarter,MED,Fiscal Year 2021 Labor HHS appropriations for Down Syndrome Research; NIH research funding,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,,0,0,2020-10-14T16:15:46.647000-04:00
2508455,77efb57d-7ad8-4856-9297-2e55efd72cbd,Q3,MICHIGAN TECHNOLOGICAL UNIVERSITY,25181,MICHIGAN TECHNOLOGICAL UNIVERSITY,2020,third_quarter,MED,Discussed issues of interest related higher education for the COVID-19 pandemic.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2020-10-15T08:18:47.857000-04:00
2508656,680033cc-0201-4016-b295-2cc7a3795b18,Q3,WINNING STRATEGIES WASHINGTON,50796,I AM ALS,2020,third_quarter,MED,Funding for ALS research in annual Defense and Labor-HHS-Education appropriations bills,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",20000,,0,0,2020-10-15T10:33:42.730000-04:00
2508752,d80ed2c1-2c1e-4093-92c2-c70432167163,Q3,WINNING STRATEGIES WASHINGTON,50796,OLIVIAN,2020,third_quarter,MED,COVID-19 face mask policy and funding opportunities,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-10-15T11:00:09.033000-04:00
2508841,f906ee76-4fe0-4225-91d8-0c1b6aad865e,Q3,WINNING STRATEGIES WASHINGTON,50796,PHILIPS NORTH AMERICA LLC,2020,third_quarter,MED,CARES Act programs and other COVID-19-related programs,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Indian Health Service,SENATE",10000,,0,0,2020-10-15T11:12:27.673000-04:00
2508850,6c992a24-305f-43a9-a3ee-d22f8f64d181,Q3,WINNING STRATEGIES WASHINGTON,50796,PHLOW CORPORATION,2020,third_quarter,MED,Domestic manufacturing of essential generic medicines; supply chain disruptions and shortages of foreign manufactured medicines,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-15T11:14:30.963000-04:00
2508880,cef90167-922a-42af-9de2-0e182103b905,Q3,WINNING STRATEGIES WASHINGTON,50796,PREMIER MEDICAL CORPORATION,2020,third_quarter,MED,COVID-19 testing policy and resources,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-15T11:21:40.197000-04:00
2508911,e5c25881-97be-44c9-8046-df5dddc73911,Q3,WINNING STRATEGIES WASHINGTON,50796,RETRACTABLE TECHNOLOGIES INC (RTI),2020,third_quarter,MED,Response to COVID-19,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-15T11:28:50.360000-04:00
2509150,521dd3c8-adc3-46f2-9385-3238304bc8ad,Q3,THE PRENDA GROUP LLC,401104543,UV-CONCEPTS,2020,third_quarter,MED,"Emergency response to COVID-19 Pandemic. Assistance to Hospitals / First Responders / Medical facilities etc. for patients, visitors, and healthcare workers. ULTRAVIOLET LIGHT ENCLOSURE TECHNOLOGY FOR BROAD APPLICATIONS IN HEALTHCARE AND NON-HEALTHCARE SECTORS. Monitoring COVID-19 Stimulus Packages and appropriations. CARES ACT HR","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-15T12:11:27-04:00
2509686,57164d6f-2394-48cb-af91-1eb702f8ab32,Q3,MARSHFIELD CLINIC HEALTH SYSTEM,57830,MARSHFIELD CLINIC HEALTH SYSTEM,2020,third_quarter,MED,"General research support, health care quality improvement, precision medicine","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,100000,0,0,2020-10-15T15:35:15.703000-04:00
2510175,9ca052c5-d56d-4048-9732-79fd043ac0ec,Q3,MICHAEL N. MCCARTY LAW OFFICE PLLC,401104300,AMERICAN MEDICAL TECHNOLOGISTS,2020,third_quarter,MED,"Appropriations for CDC initiative to establish pediatric reference intervals for clinical diagnostic testing; prospective legislation to regulate in vitro clinical diagnostic tests, including the Verifying Accurate, Leading-edge IVCT Development (VALID) Act (H.R.6102; S.3404); and the Verified Innovative Testing in American Laboratories (VITAL) Act (S.3512); Coronavirus relief and stimulus legislation as it relates to clinical laboratories and medical practices; coronavirus testing supply chain issues.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",10000,,0,0,2020-10-15T19:31:59.310000-04:00
2510310,a9baaee9-2067-45a6-ba50-a72fa15e3d80,Q3,AMERICAN SOCIETY OF ADDICTION MEDICINE,401104864,AMERICAN SOCIETY OF ADDICTION MEDICINE,2020,third_quarter,MED,"Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs.

Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period.

Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits.  Advocated for its inclusion in the Lower Health Care Costs Act of 2019.

Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn.  This bill is not specific to mental health, but it would provide significant stability to those patients and providers. 

Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release.

Supported HR 4974/S 4640:  the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes.

Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. 

Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. 

Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. 

Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes

Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings

Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19

Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose. 

Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists.
 
Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals.

Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act).

Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19

Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code.

Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be.

Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology.

Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool.

Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package.

Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments. 

Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction. 

Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package

Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system.

Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance

Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment","Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,70000,0,0,2020-10-16T08:09:01.400000-04:00
2510350,df46225a-e212-4db7-8afb-10d7272d1e3d,Q3,MANATOS & MANATOS,23634,BARBARA ANN KARMANOS CANCER INSTITUTE,2020,third_quarter,MED,PPS-exempt cancer hospitals,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-16T09:07:15.103000-04:00
2510756,1c60a46f-a26f-4880-ba48-7728f604a7cf,Q3,STANFORD UNIVERSITY,36492,STANFORD UNIVERSITY,2020,third_quarter,MED,"HR6800
Health and Economic Recovery Omnibus Emergency Solutions Act

HEALS Act  

HR8409; HR925
The Heroes Act

HR8283; S4421
Temporary Reciprocity to Ensure Access to Treatment Act

Health Professions Programs

Graduate Medical Education Funding

Pediatric GME Programs","Energy, Dept of,Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE,State, Dept of (DOS)",,100000,0,0,2020-10-16T11:38:51.980000-04:00
2511111,5e231aca-9a63-4ca1-8038-89592c72b078,Q3,"THE CONAFAY GROUP, LLC",401004840,"HAWAII BIOTECH, INC.",2020,third_quarter,MED,Medical countermeasures.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-10-16T13:17:26.107000-04:00
2511118,57b6ec7b-e2ce-4c10-bd9e-350ca836d0ee,Q3,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2020,third_quarter,MED,Monitor Data and Science policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-16T13:18:27.680000-04:00
2511353,83605c15-9800-485f-b795-8bab578f25e4,Q3,"UNIVERSITY OF MARYLAND, BALTIMORE (UMB)",401103161,"UNIVERSITY OF MARYLAND, BALTIMORE (UMB)",2020,third_quarter,MED,"H.R. 7614 Labor HHS - Education Appropriations (NIH)
CARES Act funding H.R. 748 ""Coronavirus Aid, Relief, and Economic Security Act""","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,10000,0,0,2020-10-16T14:19:24.867000-04:00
2511416,3ecc26bf-d442-4cdd-8fcc-91d687361cb8,Q3,BURRELL INTERNATIONAL GROUP LLC,401103483,SMALL BIOTECHNOLOGY BUSINESS COALITION,2020,third_quarter,MED,"Monitoring Legislation for VALID Act and Laboratory Diagnostic Testing developments;  No specific activity, nor contacts.",,,,0,0,2020-10-16T14:36:45.717000-04:00
2511428,a72fb33c-dac7-4d2f-a24c-8d54892ac0a2,Q3,BRACEWELL LLP,6837,NATIONAL BRAIN TUMOR SOCIETY,2020,third_quarter,MED,work related to the advancement of the Cancer Drug Coverage Parity Act and PCHETA (H.R. 647); Peer-review cancer research; Drug pricing and shortages; COVID-19 Response Issues,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-16T14:38:49.650000-04:00
2511458,a97df4b6-98bc-4113-944a-8869600d4c53,Q3,CAPITOL COUNSEL LLC,313715,MASSACHUSETTS BIOTECHNOLOGY COUNCIL,2020,third_quarter,MED,Monitor health and tax legislation pertaining to the biotechnology industry.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-16T14:40:02.523000-04:00
2511505,d6a52533-63f8-4234-b3a2-a6c564f13d29,Q3,"THE CONAFAY GROUP, LLC",401004840,ACADIA PHARMACEUTICALS INC.,2020,third_quarter,MED,Pharmaceutical research.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-10-16T14:50:19.307000-04:00
2511518,b94f8f57-864e-4503-89f6-e8670e022562,Q3,BURRELL INTERNATIONAL GROUP LLC,401103483,HOMOLOGY MEDICINES,2020,third_quarter,MED,"Drug pricing and gene therapy, generally;
H.R. 4393 - Advancing Access to Precision Medicine;
H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act;
H.R. 8045 - Genome Editing Threat Assessment Act;
HR 2501 - Medical Nutrition Equity Act;","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-10-16T14:54:22.630000-04:00
2511745,512f22cd-f12f-4900-a576-edccb1c8c3b4,Q3,"THE CONAFAY GROUP, LLC",401004840,"EMERJA, INC. (FORMERLY KNOWN AS WHEEL BIOLOGY, INC.)",2020,third_quarter,MED,Seek support for research and development funding,"Health & Human Services, Dept of (HHS)",10000,,0,0,2020-10-16T15:58:32.677000-04:00
2511809,440d7698-1ee9-45dd-9dd4-f3a5bbd10f52,Q3,"MCALLISTER & QUINN, LLC",292573,CEDARS-SINAI MEDICAL CENTER,2020,third_quarter,MED,"Firefighter cancer research, Congressionally Directed Medical Research Programs (CDMRP) re. healthcare/medical research.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-10-16T16:07:43.613000-04:00
2511818,2f46aab8-8f67-4239-ba37-838ceccfa8b3,Q3,"THE CONAFAY GROUP, LLC",401004840,"LUNGPACER MEDICAL USA, INC",2020,third_quarter,MED,Seek support for research and development funding.,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS)",10000,,0,0,2020-10-16T16:13:46.560000-04:00
2511868,e8880b88-00ca-4c29-8d90-040fbcb961d6,Q3,AMERICAN SOCIETY FOR CLINICAL PATHOLOGY,3435,AMERICAN SOCIETY FOR CLINICAL PATHOLOGY,2020,third_quarter,MED,Affordable Care Act; Medicare; Electronic Health Records; Health Information Technology; Medicare Access and CHIP Reauthorization Act; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Clinical Laboratory Improvement Amendments; Physician Quality Reporting System; Medicare Local Coverage Determination Reform; Medical Devices (Laboratory Tests); Stark Self-Referral Reform; Physician and Allied Health Shortages and Education; Appropriations for Federal Health Agencies; Global Health Initiative; Non-Communicable Diseases; Laboratory Access for Beneficiaries (LAB) Act; issues related to COVID-19 response and laboratory test capacity,"Bureau of Labor Statistics (BLS),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Office of Science & Technology Policy (OSTP),SENATE,Veterans Affairs, Dept of (VA),White House Office",,32000,0,0,2020-10-16T16:19:54.723000-04:00
2511896,352c9d53-4031-45f3-a4bc-bcb13fd86b5b,Q3,"THE CONAFAY GROUP, LLC",401004840,"NABRIVA THERAPEUTICS US, INC.",2020,third_quarter,MED,Support for medical countermeasure procurement.,"Health & Human Services, Dept of (HHS)",,,0,0,2020-10-16T16:27:02.393000-04:00
2511920,8a02ebda-42aa-46a5-91e6-8f63e1624ef0,Q3,"THE CONAFAY GROUP, LLC",401004840,CENTIVAX,2020,third_quarter,MED,Support for medical/disease research.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-16T16:31:08.470000-04:00
2512092,b84dfc19-3071-45f3-a693-e30f37d44dc3,Q3,"THE CONAFAY GROUP, LLC",401004840,"ATEA PHARMACEUTICALS, INC.",2020,third_quarter,MED,Support for medical/disease research.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-16T16:56:54.617000-04:00
2512120,44cf30cf-49af-4b29-82a4-10982ad462e7,Q3,"MCHUGH LEMAY ASSOC., LLC",401105253,CLARK STREET ASSOCIATES LLC ON BEHALF OF QORVO,2020,third_quarter,MED,Issues related to COVID testing - no specific leghislation.,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-16T17:01:04.840000-04:00
2512164,6856c669-f9c2-4bca-bcd4-55a242bb3c49,Q3,"THE CONAFAY GROUP, LLC",401004840,"PHASEBIO PHARMACEUTICALS, INC",2020,third_quarter,MED,Support for medical/disease research.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-16T17:16:21.057000-04:00
2512317,f352ebbe-5443-428f-930f-2a5ae4bbe1f8,Q3,"THE CONAFAY GROUP, LLC",401004840,EMERGEX VACCINES HOLDING LTD.,2020,third_quarter,MED,Influenza and respiratory disease research,SENATE,,,0,0,2020-10-16T18:02:52.363000-04:00
2512322,5d7926eb-ba31-49de-8b46-82470c830d43,Q3,"THE CONAFAY GROUP, LLC",401004840,"PREACTIVE TECHNOLOGIES, INC.",2020,third_quarter,MED,Traumatic Brain Injury Prevention,SENATE,,,0,0,2020-10-16T18:05:53.333000-04:00
2512327,56ed90e1-789f-4903-b129-15853334d30f,Q3,"TOWNSEND PUBLIC AFFAIRS, INC",54734,CITY OF PARLIER,2020,third_quarter,MED,health benefits legislation,"HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE",7500,,0,0,2020-10-16T18:07:54.050000-04:00
2512332,336ab40c-3fc8-4301-96f7-74e050e1e2ee,Q3,"THE CONAFAY GROUP, LLC",401004840,"ROIVANT SCIENCES, INC.",2020,third_quarter,MED,Support for medical/disease research.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-16T18:10:55.877000-04:00
2512493,8805842c-c22f-4f4d-b037-71c025b08918,Q3,IMPACT HEALTH POLICY PARTNERS,401104696,ABBOTT LABORATORIES,2020,third_quarter,MED,"Issues related to coverage and reimbursement for durable medical equipment, medical devices, diagnostics and nutrition.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-10-16T22:40:49.020000-04:00
2512495,68fa8332-052b-4824-9d67-2172d1f88391,Q3,IMPACT HEALTH POLICY PARTNERS,401104696,HACKENSACK MERIDIAN HEALTH,2020,third_quarter,MED,"Issues related to research funding, NIH and other matters.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-16T22:54:50.380000-04:00
2512499,6912c9f3-3959-44da-bc48-120e831b3ead,Q3,IMPACT HEALTH POLICY PARTNERS,401104696,CHILDREN'S HOSPITAL COLORADO,2020,third_quarter,MED,Issues related to pediatric research and children's hospital graduate medical education.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-16T23:17:51.720000-04:00
2512920,7296df17-b044-485e-a5a3-35f30880f707,Q3,FAEGRE DRINKER BIDDLE & REATH LLP,12631,DRUGS FOR NEGLECTED DISEASES INITIATIVE OF NORTH AMERICA,2020,third_quarter,MED,Issues related to anti-microbial resistance and neglected tropical diseases.,,10000,,0,0,2020-10-17T15:40:37.397000-04:00
2512921,f4f75c6e-6030-416d-9350-78c39d812e7e,Q3,FAEGRE DRINKER BIDDLE & REATH LLP,12631,AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE,2020,third_quarter,MED,"Public Health Programs for Infectious and Tropical Disease; HR 7308 - The RISE Act;  S.474, a bill to address the public health risks posed by wildlife markets, and for other purposes.",Office of Management & Budget (OMB),50000,,0,0,2020-10-17T15:41:37.793000-04:00
2512939,055b38e7-96ef-4813-b415-1d98e5716a9b,Q3,FAEGRE DRINKER BIDDLE & REATH LLP,12631,SIMON WILLIAMS PHARMA CONSULTING (SWPC) LLC,2020,third_quarter,MED,Pandemic preparedness.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-17T15:47:42.140000-04:00
2513192,3da83d90-1246-44f5-9092-fade1f0c500a,Q3,OGR,48827,SMITHS GROUP PLC,2020,third_quarter,MED,"Medical device technology related to the opioid epidemic and the COVID-19 pandemic.
H.R.5172/S.3067, NOPAIN Act.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-10-18T00:01:55.793000-04:00
2513259,44322b8f-1fa6-43c8-adcc-118e0c4a58c8,Q3,FORBES-TATE,400976792,"AMGEN USA, INC.",2020,third_quarter,MED,Issues related to Biosimilars.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-10-18T09:06:42.263000-04:00
2513478,c5aa905f-1d61-47dc-879d-22029af90add,Q3,OGR,48827,WEAVR HEALTH,2020,third_quarter,MED,COVID-19 serology issues,,10000,,0,0,2020-10-18T12:21:53.153000-04:00
2513485,f1d79ed0-78cd-4f45-b571-8dcc1afdeb76,Q3,"THE PETRIZZO GROUP, INC.",305932,SEATTLE CHILDREN'S HOSPITAL RESEARCH AND FOUNDATION,2020,third_quarter,MED,"Funding for NIH research; H.R. 4159, PACT Act.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2020-10-18T12:57:56.387000-04:00
2513495,804af85a-028f-42d1-a09b-cb7ca42b46c2,Q3,"THE PETRIZZO GROUP, INC.",305932,ALLEN INSTITUTE,2020,third_quarter,MED,"Advocated for funding of the BRAIN Initiative, Alzheimer's research full funding for NIH. Advocated for the development of open data hosting, and integrated, scalable data analysis hubs for the BRAIN Initiative at NIH. The Human Projectome Project, a comprehensive Atlas of cell types in human brain and the Mouse Connectome Project for BRAIN Initiative","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2020-10-18T13:00:57.920000-04:00
2513496,7b03161e-3098-427c-8d32-7c86a2f0a96b,Q3,"THE PETRIZZO GROUP, INC.",305932,CEL-SCI CORPORATION,2020,third_quarter,MED,"Activity related to phase III clinical trial in head and neck cancer to boost the immune system before the ravages of surgery, radiation and chemotherapy. The Phase III trial is the largest ever in head and neck cancer with 928 patients enrolled. 
LEAPS COVID-19 Immunotherapyas a new immune-based treatment for COVID-19","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Vice President of the U.S.",50000,,0,0,2020-10-18T13:02:58.370000-04:00
2513500,3f1104c4-19d8-447e-8472-7d765d0711b5,Q3,"THE PETRIZZO GROUP, INC.",305932,ACCESS TO ADVANCED HEALTH INSTITUTE,2020,third_quarter,MED,Advocating for funding for COVID-19 vaccine and therapy development and manufacturing; support adjuvant inclusion in COVID-19 countermeasures.,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",20000,,0,0,2020-10-18T13:03:59.307000-04:00
2513642,f9fc22ea-08e8-48cc-96d9-2394c03be47d,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,ABBVIE,2020,third_quarter,MED,"Issues related to pharmaceutical manufacturing
Issues related to treatment of endometriosis","HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of",60000,,0,0,2020-10-18T15:25:32.587000-04:00
2513916,56c3eb12-608b-4e03-ae3e-09b9e64763c6,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,"ANTHEM, INC.",2020,third_quarter,MED,"Issues related to Medicare
H.R. 748 CARES Act - Issues related to COVID-19 relief","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2020-10-18T19:16:50.217000-04:00
2513978,e4b8b0d7-6904-4bd9-ba6c-255c7b7d605e,Q3,PARALYZED VETERANS OF AMERICA,30724,PARALYZED VETERANS OF AMERICA,2020,third_quarter,MED,"Department of Veterans Affairs, Medical Research Issues
National Institutes of Health, Medical Research Issues","AMTRAK - Natl Railroad Passenger Corporation,Centers For Medicare and Medicaid Services (CMS),Education, Dept of,Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),Justice, Dept of (DOJ),Labor, Dept of (DOL),Natl Institutes of Health (NIH),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Architectural & Transportation Barriers Compliance Board (ACCESS),Veterans Affairs, Dept of (VA),Veterans Employment & Training Service",,78368,0,0,2020-10-18T21:32:11.223000-04:00
2514011,f0d5116a-b535-4c76-b97d-c434e5d655b7,Q3,"THE NICKLES GROUP, LLC",293335,"MYRIAD GENETICS, INC.",2020,third_quarter,MED,"S 3404, VALID Act and regulation of pharmcogenomic tests.","Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-10-18T21:50:17.507000-04:00
2514159,e062ffc0-e953-4665-bf4e-8716ddbfb040,Q3,FOLEY & LARDNER LLP,15042,NOVOCURE INC.,2020,third_quarter,MED,"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",100000,,0,0,2020-10-18T22:44:57.873000-04:00
2514202,f0fbc217-2f14-4679-ac26-6f1ef895fc71,Q3,FOLEY & LARDNER LLP,15042,SHINE MEDICAL TECHNOLOGIES,2020,third_quarter,MED,Implementation of American Medical Isotope Production Act,,,,0,0,2020-10-18T22:59:06.323000-04:00
2514403,fe2c38e4-b172-4e36-b99d-c4666e553648,Q3,VAN SCOYOC ASSOCIATES,39837,"ARUP LABORATORIES, INC.",2020,third_quarter,MED,"H.R.6102, Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, Diagnostic Lab Testing

Public Law 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act, COVID-19 Laboratory Testing related issues

Public Law 116-139, Paycheck Protection Program and Health Care Enhancement Act, COVID-19 Laboratory Testing related issues

Future Coronavirus relief related issues, COVID-19 Laboratory Testing related issues




Monitor COVID-19 Laboratory Testing related issues, as follows:

Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, FY2020 

Public Law 116-127, Families First Coronavirus Response Act","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-19T06:42:56.477000-04:00
2514471,d1b62b1c-9088-458e-8ae2-858b4d65753a,Q3,VAN SCOYOC ASSOCIATES,39837,GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION,2020,third_quarter,MED,"CDC, Infectious Diseases

Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, FY2020, Higher Education research related issues; and SARS-CoV2 issues

Public Law 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act, Higher Education research related issues; and SARS-CoV2 issues

E-Cigarettes related issues




Monitor the following:

Agency for Healthcare Research and Quality

Medicaid Disparities NIH

Public Health

Research Centers in Minority Institutions","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-19T07:34:09.863000-04:00
2514480,1a831718-cde2-4532-a75e-837c55f71faa,Q3,VAN SCOYOC ASSOCIATES,39837,UNIVERSITY OF TOLEDO,2020,third_quarter,MED,"Higher Education research related issues; and SARS-CoV2 issues, as follows:

Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, FY2020

Public Law 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-10-19T07:36:10.937000-04:00
2514640,664e68df-ea2c-4955-a6bd-ee5b7c69f206,Q3,UC HEALTH,401103195,UC HEALTH,2020,third_quarter,MED,"COVID19 Testing Equipment and Supplies (swabs, reagents), convalescent plasma studies, Moderna Vaccine Trial, Operation Warp Speed","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-10-19T09:05:43.447000-04:00
2514878,0a33385c-eef8-439b-a6f5-4f5211347102,Q3,VAN SCOYOC ASSOCIATES,39837,MEDICAL COLLEGE OF WISCONSIN,2020,third_quarter,MED,"H.R.4764, Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies Act of 2019 or the TRANSPLANT Act of 2019"", Reauthorization related issues





Monitor Healthcare research and development related issues, as follows:

Department of Defense Medical research issues

H.R.7613, Energy and Water Development and Related Agencies Appropriations Act, FY2021

H.R.7614, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2021

H.R.7616, Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, FY2021

Public Law 116-136, Coronavirus Aid Relief and Economic Security (CARES) Act, Implementation issues",SENATE,30000,,0,0,2020-10-19T09:40:46.960000-04:00
2514885,dd7e2994-5687-4a40-96a8-6b88cd43c081,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,BAXTER HEALTHCARE CORPORATION,2020,third_quarter,MED,Availability of medical products,HOUSE OF REPRESENTATIVES,30000,,0,0,2020-10-19T09:41:48.523000-04:00
2514906,5b5064b7-e8f0-48a2-bec7-f97469165f3b,Q3,"K&L GATES, LLP",32098,"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.",2020,third_quarter,MED,"Export restrictions for research models from China -- no specific legislation. 
New facilities for research models -- no specific legislation.","Federal Aviation Administration (FAA),White House Office",10000,,0,0,2020-10-19T09:45:54.007000-04:00
2514958,ab795d1d-ef12-477a-b7bb-4ec3c650aea5,Q3,THE NATIONAL ALLIANCE FOR EYE AND VISION RESEARCH,314055,THE NATIONAL ALLIANCE FOR EYE AND VISION RESEARCH,2020,third_quarter,MED,"Support for Medical Research Funding Programs at the National Institutes of Health, the National Eye Institute, and the Department of Defense","HOUSE OF REPRESENTATIVES,SENATE",,67782,0,0,2020-10-19T09:54:05.583000-04:00
2515016,5b5ac6e3-58ed-4291-a79e-590a89f9e023,Q3,VAN SCOYOC ASSOCIATES,39837,MEDICAL UNIVERSITY HOSPITAL AUTHORITY,2020,third_quarter,MED,"Monitor Medical research and development related issues:

National Institutes of Health and various institutes and bureaus thereof

Health Resources Services Administration","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-10-19T09:57:13.767000-04:00
2515073,aacd737e-f3ae-47c7-ad12-66d2af3f921c,Q3,"THE CONAFAY GROUP, LLC",401004840,"CIDARA THERAPEUTICS, INC.",2020,third_quarter,MED,Support for research on viral diseases,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-10-19T10:02:27.190000-04:00